Endocrinology, Vol 137, 5530-5536, Copyright © 1996 by Endocrine Society

ARTICLES

Characterization and determination of the relative abundance of two types of insulin-like growth factor binding protein-5 proteases that are secreted by human fibroblasts

TJ Nam, WH Busby Jr and DR Clemmons
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill 27599, USA.

We previously reported that human fibroblasts secrete a protease into their conditioned medium that cleaves insulin-like growth factor binding protein-5 (IGFBP-5) into non-IGF-I binding fragments. Because the protease activity in the fibroblast medium has characteristics of both serine and metalloproteases, the activity was purified and analyzed to determine whether it retained serine or metalloprotease properties. The protease was purified by heparin Sepharose affinity chromatography followed by alpha1 antichymotrypsin affinity or gelatin agarose chromatography. The heparin Sepharose purified material degraded IGFBP-5 into 22-, 17-, and 16-kDa fragments. Amino acid sequencing showed that the 22-kDa fragment contained the amino-terminus of the protein. The protease activity in the fibroblast conditioned medium that was purified by heparin Sepharose was inhibited by both serine and metalloprotease inhibitors. To attempt to separate these activities, the heparin Sepharose purified activity was further purified by gelatin agarose chromatography. The IGFBP-5 protease activity that did not bind to gelatin agarose was inhibited by serine protease inhibitors, such as 3,4 dichloroisocoumain (3,4 DCI), whereas tissue inhibitor metalloprotease-1 (TIMP-1) had minimal activity. When this same pool of protease activity that had been eluted from heparin Sepharose was applied to an alpha1 antichymotrypsin peptide affinity column, the protease activity that bound to the column was inhibited by 3,4 dichloroisocoumain, but was not inhibited by TIMP-1. In contrast, the activity that did not adhere to this column was inhibited by TIMP- 1. IGFBP-5 zymography showed that the Mr estimate of the protease that was inhibited by serine protease inhibitors was 92 kDa, whereas gelatin zymography showed that the metalloproteases had Mr estimates of 72, 69, and 55 kDa. When the protease activity in the crude conditioned medium was analyzed by zymography, almost all of the detectable protease had an Mr estimate of 92 kDa, suggesting that the metalloproteases that were detected in the partially purified fractions were inactive in the medium. In summary, fibroblasts secrete a 92-kDa protease that cleaves IGFBP-5 into 22-, 17-, and 16-kDa fragments. The protease inhibitor specificity results, chromatographic characteristics, and zymographic analyses suggest that this is a serine protease. Although metalloproteases are secreted by these cells, the 92-kDa serine protease is the predominate form of activity in the conditioned medium that cleaves IGFBP-5.

This article has been cited by other articles:

				C. K. Wieslander, S. I. Marinis, P. G. Drewes, P. W. Keller, J. F. Acevedo, and R. A. Word Regulation of Elastolytic Proteases in the Mouse Vagina During Pregnancy, Parturition, and Puerperium Biol Reprod, March 1, 2008; 78(3): 521 - 528. [Abstract] [Full Text] [PDF]

				S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF]

				R. D. Devlin, Z. Du, V. Buccilli, V. Jorgetti, and E. Canalis Transgenic Mice Overexpressing Insulin-Like Growth Factor Binding Protein-5 Display Transiently Decreased Osteoblastic Function and Osteopenia Endocrinology, October 1, 2002; 143(10): 3955 - 3962. [Abstract] [Full Text] [PDF]

				T. Nam, A. Moralez, and D. Clemmons Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions Endocrinology, January 1, 2002; 143(1): 30 - 36. [Abstract] [Full Text] [PDF]

				D. R. Clemmons Use of Mutagenesis to Probe IGF-Binding Protein Structure/Function Relationships Endocr. Rev., December 1, 2001; 22(6): 800 - 817. [Abstract] [Full Text] [PDF]

				E. M. Zimmermann, L. Li, Y. T. Hou, N. K. Mohapatra, and J. B. Pucilowska Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn's disease Am J Physiol Gastrointest Liver Physiol, May 1, 2001; 280(5): G1022 - G1029. [Abstract] [Full Text] [PDF]

				T. Kikuchi, T. Abe, M. Yaekashiwa, Y. Tominaga, H. Mitsuhashi, K. Satoh, T. Nakamura, and T. Nukiwa Secretory Leukoprotease Inhibitor Augments Hepatocyte Growth Factor Production in Human Lung Fibroblasts Am. J. Respir. Cell Mol. Biol., September 1, 2000; 23(3): 364 - 370. [Abstract] [Full Text]

				T.S. Gadd, J.C. Osgerby, and D.C. Wathes Regulation and Localization of Insulin-Like Growth Factor Binding Protein-5 Gene Expression in the Uterus and Placenta of the Cyclic and Early Pregnant Ewe Biol Reprod, May 1, 2000; 62(5): 1415 - 1421. [Abstract] [Full Text]

				E. Gazzerro, S. Rydziel, and E. Canalis Skeletal Bone Morphogenetic Proteins Suppress the Expression of Collagenase-3 by Rat Osteoblasts Endocrinology, February 1, 1999; 140(2): 562 - 567. [Abstract] [Full Text]

				X. Qin, D. D. Strong, D. J. Baylink, and S. Mohan Structure-Function Analysis of the Human Insulin-like Growth Factor Binding Protein-4 J. Biol. Chem., September 4, 1998; 273(36): 23509 - 23516. [Abstract] [Full Text] [PDF]

				B. Gabbitas and E. Canalis Insulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts Am J Physiol Endocrinol Metab, August 1, 1998; 275(2): E222 - E228. [Abstract] [Full Text] [PDF]

				B. Kubler, S. Cowell, J. Zapf, and T. Braulke Proteolysis of Insulin-Like Growth Factor Binding Proteins by a Novel 50-Kilodalton Metalloproteinase in Human Pregnancy Serum Endocrinology, April 1, 1998; 139(4): 1556 - 1563. [Abstract] [Full Text] [PDF]

				B. Zheng, J. B. Clarke, W. H. Busby, C. Duan, and D. R. Clemmons Insulin-Like Growth Factor-Binding Protein-5 Is Cleaved by Physiological Concentrations of Thrombin Endocrinology, April 1, 1998; 139(4): 1708 - 1714. [Abstract] [Full Text] [PDF]

				N. Franchimont, D. Durant, and E. Canalis Interleukin-6 and Its Soluble Receptor Regulate the Expression of Insulin-Like Growth Factor Binding Protein-5 in Osteoblast Cultures Endocrinology, August 1, 1997; 138(8): 3380 - 3386. [Abstract] [Full Text] [PDF]

				M. Potter, J. Wax, and G. M. Jones Indomethacin Is a Potent Inhibitor of Pristane and Plastic Disc Induced Plasmacytomagenesis in a Hypersusceptible BALB/c Congenic Strain Blood, July 1, 1997; 90(1): 260 - 269. [Abstract] [Full Text] [PDF]

				W. H. Busby Jr., T.-J. Nam, A. Moralez, C. Smith, M. Jennings, and D. R. Clemmons The Complement Component C1s Is the Protease That Accounts for Cleavage of Insulin-like Growth Factor-binding Protein-5 in Fibroblast Medium J. Biol. Chem., November 22, 2000; 275(48): 37638 - 37644. [Abstract] [Full Text] [PDF]